-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...
More »SEARCH RESULT
When innovation is under threat-Swati Piramal
-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...
More »Rx: Make All clinical trial Data Public
-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European Medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...
More »European Union-India FTA may hit generic medical industry-Rema Nagarajan
-The Times of India The free trade agreement that European Union is pushing India to sign could put an end to India's status as the pharmacy of the developing providing affordable medicines, especially HIV drugs to countries like Brazil, Thailand, South Africa, Zimbabwe and several others. The negotiations with EU are on at a feverish pace this week in Brussels even before the parliamentary standing committee looking into the free trade...
More »Committee on drugs calls for 20 sub-panels-Vidya Krishnan
-Live Mint An investigation found DCGI cleared drugs without conducting mandatory clinical trials After five rounds of consultations in six months, a committee tasked with making recommendations on cleaning up India’s drugs-approval process and ending the cosy relationship between doctors, pharmaceutical companies and government officials had no suggestions to offer by way of a crackdown. It has, instead, suggested setting up 20 sub-committees. The report submitted to the health ministry in November is...
More »